Member Info for TrekMadone

And this I why I have said for a while now Nasdaq soon.....

“ In October 2017, Ablynx launched on the NASDAQ stock exchange after 10 years on the Euronext stock exchange. With an IPO of $175M (€148M), a subsequent leap in share price and its 2018 acquisition by Sanofi, it’s hard to deny that it was a successful move by the company.”

Trek

Recalling the panorama coverage of Covid 19 they touched on the vaccine tests. My apologies but I don’t remember the numbers but basically you take say 300 healthy people give half the vaccine and half the placebo and say go and get on with your lives then come back in 6 months.

Fast forward 6 months and they look at the two groups and if some percentage got Covid from the placebo group and percentage didn’t get it from the vaccine group then the Oxford trial was a success! I thought wtf!

Now they are obviously very clever people but don’t they know about social distancing? Geographical differences in No of cases? I mean I thought you vaccinated and then gave them some controlled exposure like in Open Orphans clinics but nope it’s just a mathematical lottery! Obviously just my naive view but good luck with that one!

Trek

“Closing my LSE account tomorrow and getting on with my life as very happy with all my investments.”

Thank you for your outstanding contribution to this and other BB’s. I often just click on your handle to check the news by just reading your posts! Top posts and you are an active investor that has made a difference!

I fully understand your reasons as I spend too much time on here!

Good luck my virtual friend with whatever you do and always remember ‘health is wealth’.

Trek

Because there are more sellers than buyers. Profit taking, hot money jumping stocks, ii selling. They are traded on SETSqx so at the end of the day such a shift is mathematical.

Trek

Post-Halving Reality: 17% Of Miner Revenue is Coming From Fees

In the post-halving reality, Bitcoin miners revenue has dropped by over 60 percent.

With the block reward cut in half, miners are relying on Bitcoin (BTC) transaction fees to sustain themselves to a much greater extent.

Miners lost 61% of their revenue

May 10, miners earned 2188 BTC, May 12, this number fell to 852 BTC — a 61% drop. The halving of the block reward forced some miners off the chain, reducing the network hashrate. This in turn led to the increase in block interval, meaning that fewer block processed in a unit of time, decreasing the number of block rewards available to the miners.

Mini Death spiral phase

What has unfolded thus far could be called a mini death spiral scenario. The only saving grace for miners is that network congestion has led to a sharp increase in the cost of transaction fees — from $0.62 at the end of April to $5.21 on May 15. Currently, as a result of this dynamic, transaction fees account for 17% of the miners’ revenue. This is the highest proportion since January 2018.

Miners revenue denominated in USD has declined from $19.25 million on May 9 to $7.82 million on May 12; a 62% decrease. The next difficulty adjustment will take place in three days. However, live calculation is predicting an increase in difficulty because the hashrate grew substantially prior to the halving. However, by the time it comes around, there will likely be a small decrease in the difficulty, which should help the remaining miners.

It is possible that as Bitcoin matures and each new halving further cuts the block reward until eventually, there are no more new Bitcoins to mine, that miners will have to rely more on the fees. However, higher fees will make the network less attractive for the users.

As Cointelegraph reported earlier, paradoxically, many of the mining industry insiders believe that the drop in hashrate is a bullish sign for Bitcoin as it will make the remaining miners more profitable.”

https://cointelegraph.com/news/post-halving-reality-17-of-miner-revenue-is-coming-from-fees

Trek

£1

Sorry last link cut off...

https://www.londonstockexchange.com/prices-and-markets/prices-help/trade-type.htm

Trek

Late trades...sections g3013 and g3020 key. Nothing sinister and MiFID compliant...

In relation to rule 3012, where two member firms agree at or prior to the time of the trade, the responsibility for trade reporting may be delegated to the other member firm.

The rule recognises that member firms may wish to delegate the trade reporting responsibility to the other member firm. This may arise where a member firm trades infrequently and hence wishes to always delegate the reporting process or where the non reporting member firm wishes to gain protection under the deferred publication facility but the reporting member firm does not.
(Amended N09/17 – effective 3 January 2018)
Standard trade report deadlines [3020-3021]

Where a trade is executed during the trade reporting period, a trade report shall be submitted to the trading system in accordance with the standard trade report deadline.

Guidance to Rule:
The trading system will immediately publish a trade report unless deferred
publication is requested (and the trade qualifies for a delay). (Amended N09/17 – effective 3 January 2018)

And these are the addressable concerns

A member firm shall not:
aggregate trades in order to qualify for treatment under the deferred publication facility; add subsequent trades to a deferred publication in order to increase its size; or
submit or agree to submit a correction for the sole purpose of re-reporting a trade in order to gain or extend a delay in publication.

And here is a less technical explanation.....from FAQ’s

When can the deferred publication regime be used?

A member firm should only request deferred publication where the member firm is dealing on its own account (as principal) and the transaction is between the member firm and its customer.

How can I request deferred publication of a trade?

A member firm may request deferred publication of a trade by submitting a trade report with either the ‘OK’ (for an ordinary trade) or ‘NK’ (for a negotiated trade) trade type. MillenniumIT will determine whether a delay should be applied based on the relevant publication regime.

References....

Handbook
https://www.londonstockexchange.com/traders-and-brokers/rules-regulations/rules-lse.pdf

FAQ’s
https://www.londonstockexchange.com/traders-and-brokers/membership/faqs/rulebook-faq/rulebook-faqs.htm

Trade flags/types
https://www.londonstockexchange.com/price

Trek

Buys as sells....

The red blue shown are indicative but pretty accurate as long as the spread is consistent and the sp is not moving too quickly. The algorithm is based on the trade being above or below the midpoint to determine if it’s a buy or sell.

The problems that occur are...
If the spread is wide a buy can be below the mid point if there is a MM with a liquid book that can match the trade. So a buy can be posted as a sell and vice versa. So watch the spread.

If the SP is falling quickly then sells can look like buys.
If the sp is rising quickly then buys look like sells.

So if there is say a 2-3% spread and the vix is pretty stable for the day the buy/sell figures have a good degree of reliability.

Trek

Hi Scart, yes good spot, and it’s always worth reading what is going on across the sector, I posted this having posted it on SNG.... May would indeed be optimistic. From May 1st RNS...

“David Budd, Chief Executive Officer of genedrive plc, says: "We are very pleased to have passed these technical milestones and with CE marking planned we will offer our novel high throughput test in the near future. ...”

Trek

Not sure if already posted as lost the will will the bogus ceo diatribe and gullibility...

Diagnostics and equipment
Several companies are focusing on serology tests, which target antibodies to see whether the person has had the virus. According to analysts at Credit Suisse, they are “critical” in understanding immunity and potentially lift restrictions. Abbott and Eurofins announced the launch of their tests in mid-April, while Roche's Elecsys received approval in the US and Europe, with the UK in talks to secure a contract. The Swiss giant is ramping up production “to high double-digit millions per month”.
Novacyt PLC (LON:NCYT) has been one of the pioneers in swab testing, launching the first kit in February, followed by a second one, designed to deliver faster results, in March. It is manufacturing 4mln tests per month. It is also developing a new test that does not require certain extraction reagents which are lacking throughout the market.
Genedrive PLC (LON:GDR) is developing a test, set to be approved in May, to deliver results quickly in close proximity to patients, rather than needing to send samples to labs to be tested and waiting for a conclusive result.
Inspiration Healthcare Group PLC (LON:IHC) has boosted production of ventilator machines and other crucial medical equipment for the UK.

Full article is worth a read...

https://www.proactiveinvestors.co.uk/companies/news/917772/coronavirus-whats-happening-in-the-labs-of-pharma-companies-worldwide-917772.html

Trek

You can finance the shares and transfer them thereafter by completing a stock transfer form. I did similar in the old days to wife’s name. Just need to watch out for tax.

Trek

Diagnostics and equipment
Several companies are focusing on serology tests, which target antibodies to see whether the person has had the virus. According to analysts at Credit Suisse, they are “critical” in understanding immunity and potentially lift restrictions. Abbott and Eurofins announced the launch of their tests in mid-April, while Roche's Elecsys received approval in the US and Europe, with the UK in talks to secure a contract. The Swiss giant is ramping up production “to high double-digit millions per month”.
Novacyt PLC (LON:NCYT) has been one of the pioneers in swab testing, launching the first kit in February, followed by a second one, designed to deliver faster results, in March. It is manufacturing 4mln tests per month. It is also developing a new test that does not require certain extraction reagents which are lacking throughout the market.
Genedrive PLC (LON:GDR) is developing a test, set to be approved in May, to deliver results quickly in close proximity to patients, rather than needing to send samples to labs to be tested and waiting for a conclusive result.
Inspiration Healthcare Group PLC (LON:IHC) has boosted production of ventilator machines and other crucial medical equipment for the UK.

https://www.proactiveinvestors.co.uk/companies/news/917772/coronavirus-whats-happening-in-the-labs-of-pharma-companies-worldwide-917772.html

Trek

New treatment
GlaxoSmithKline PLC (LON:GSK) and Vir Biotechnology Inc (NASDAQ:VIR) are cooperating to research coronaviruses using Vir’s antibody platform technology.
Tiziana Life Sciences PLC (LON:TILS) has developed a handheld inhaler that will allow the rapid delivery of TZLS-501, its drug to treat inflammation of the lung caused by the coronavirus.
The NHS is preparing to test the blood of coronavirus survivors to see if it can be used to treat patients.
Other groups are working on antibodies from people who have recovered, such as Takeda, Mount Sinai and Hopkins. The results can be used by vaccine developers as they will help understanding how the immune system works, said Tim Xu, investment associate at venture capital company Arix Bioscience PLC (LON:ARIX).


Vaccines
The Jenner Institute at Oxford University could have a few million doses ready as early as September and signed a deal with AstraZeneca PLC (LON:AZN), which will produce and distribute the jab.
GlaxoSmithKline PLC (LON:GSK) and French rival Sanofi have agreed to develop a candidate that is scheduled to enter clinical trials in the second half of 2020 and be ready by 2021.
Biotech company Moderna Inc (NASDAQ:MRNA) developed a candidate in only 63 days, entering trials in March. If ready it could be available to some professional categories by autumn 2020.
Johnson & Johnson (NYSE:JNJ) has pencilled in human clinical studies by September, with the first batches potentially available for emergency use authorisation in early 2021.
Pfizer Inc. (NYSE:PFE) teamed up with BioNTech (NASDAQ:BNTX) to develop four candidates, with clinical trials having started in Germany and the US.
Frontier IP Group PLC’s (LON:FIPP) portfolio company The Vaccine Group is working on formulations for animals to prevent coronaviruses from infecting humans again.
German company CureVac was subject to a tug of war between the country's government and Donald Trump, who prompted outrage by attempting to buy the low-cost coronavirus vaccine developer in March.
Other candidates are being studied by Inovio, the Shenzhen Geno-Immune Medical Institute, CanSino Biologicals and a partnership between Soligenix and the University of Hawaii.

Trek

Existing drugs being repurposed
Gilead Sciences Inc’s (NASDAQ:GILD) antiviral medication remdesivir received temporary approval by the US authorities for Covid-19 treatment. The firm also agreed with five generics producers to supply it in 127 countries. Three trials confirmed that remdesivir allows for a faster recovery in patients with severe symptoms, while other studies are ongoing to confirm its safety and efficacy.
AstraZeneca PLC (LON:AZN) is assessing the efficacy of Calquence, normally used for blood cancer.
Sanofi is focusing on Plaquenil/Hydroxychloroquine, used for malaria, and rheumatoid arthritis treatment Kevzara in conjunction with Regeneron.
Another repurposed arthritis treatment is Swiss giant Roche’s Actemra, with clinical results expected between June and July
Fellow Swiss conglomerate Novartis is evaluating canakinumab, a fully-human antibody, and ruxolitinib, a treatment for bone marrow disorders.
Ergomed PLC (LON:ERGO) is running trials for two antibodies, namilumab (IZN-101) and siltuximab. Interim data on the latter showed that 33% of patients saw clinical improvement, with a reduced need for oxygen support, while 43% stabilised.
Respiratory drug developer Synairgen PLC (LON:SNG) is testing its candidate SNG001, a formulation based on interferon beta, a naturally occurring protein which orchestrates the body's antiviral responses.
CytoDyn Inc begun the first human trials for leronlimab (PRO 140), initially designed to treat HIV, in mid-April.
The University of Dundee is testing brensocatib, a treatment originally designed for long-term lung conditions. The project is funded by Insmed Incorporated (NASDAQ:INSM), the developer of the drug.
The University of Oxford is conducting two trials: ‘PRINCIPLE’, testing the anti-malarial drug Plaquenil-Hydroxychloroquine, and 'RECOVERY', involving several drugs: Lopinavir-Ritonavir (commonly used to treat HIV), Dexamethasone (a type of steroid, which is used in a range of conditions typically to reduce inflammation), Hydroxychloroquine (related to an anti-malarial drug), Azithromycin (a commonly used antibiotic), Tocilizumab (an anti-inflammatory treatment given by injection).

Trek

I posted a response on AVCT to Sorrento and Mount Sinai link up. It basically uses a decoy to bind the SARS-Cov 2 virus. The decoy is more attractive than ACE2. My wife a cancer survivor takes drugs that work on a similar level. The science is sound but you can’t treat everyone and it only last for a couple of months tops. So for sure if it gets FDA it will have a place, say an outbreak on an aircraft carrier, a cluster in a city but I doubt it could be a silver bullet.... here are some others on next post...

Trek

“Touchstone
First quarter results and operational update from Touchstone yesterday where the company has changed somewhat since such incredible success at Ortoire. For example 1Q production was 1,589 b/d (2,121) and 1,690 in 4Q 2019 as the company concentrates on the bigger potential plays in its portfolio. COVID-19 has delayed timing of capital projects but apart from that has not materially impacted the company.

The company has invested $1,823,000 in exploration activities, completing two successful production tests on the Cascadura-1ST1 exploration well and completing lease preparations on the Chinook-1 exploration well site where TXP ‘currently anticipate drilling the well in July 2020. At present the plan is to then drill a deeper well at the Cascadura field where the company has an option and to complete that before the Royston location which would entail construction costs and potential delays.

Touchstone has done very well with its discoveries on the Ortoire block and it is clearly continuing to progress work there for the future, this will please shareholders and there should be further to go for the shares.”

https://www.malcysblog.com/2020/05/oil-price-petrofac-lamprell-touchstone/

Trek

“The process of discovering an antibody-based treatment

AstraZeneca scientists are exploring three potential sources for antibodies against the SARS CoV-2 virus – patients who have recovered from COVID-19, immunised humanised mice and laboratory techniques such as phage display.

The spike protein on the SARS-CoV-2 virus is the primary target being explored for potential COVID-19 monoclonal antibodies. The aim is that by targeting the spike protein, the antibody will be able to neutralise the SARS-CoV-2 virus and affect its capacity to infect healthy cells.

AstraZeneca is harnessing its proprietary immune replica technology, developed as part of the abovementioned agreement with DARPA, which can capture and screen antibodies from millions of primary B cells. The company is also utilising hybridoma technology, which is a method for producing large numbers of monoclonal antibodies through a culture of hybrid cells that results from the fusion of B cells and immortal myeloma cells.

Once identified, the monoclonal antibodies are screened against their ability to bind to the spike protein before further developability tests are carried out. AstraZeneca is aiming for clinical evaluation in the next 3 to 5 months.

It is hoped that this multi-pronged approach will increase the chances of discovering potential monoclonal antibodies against this virus. Should any of the antibodies progress through to development and subject to scale up and regulatory approvals, AstraZeneca has end-to-end capabilities for development, manufacturing and distribution of monoclonal antibodies.“

Step up Avacta now they have put the look at what we have RNS out to the Pharma world!

https://www.astrazeneca.com/media-centre/articles/2020/researching-antibodies-to-target-covid-19.html#!

Trek

Similar principle to how camostat mesylate works, prevents entry into the host cell by inhibiting TMPRSS2 activity.

For SARS-CoV entry into a host cell, its S protein needs to be cleaved by cellular proteases at 2 sites, S protein priming, this enables the viral and cellular membranes can fuse, known as S protein priming by TMPRSS2. This is what is crucial for SARS-CoV infection of the target cells and spreading throughout the host which can lead to ACE2 upregulation and cytokine storm (multiple organ failure). S protein priming occurs by TMPRSS2 cleaving so the body duffs itself up. Treatment with the serine protease inhibitor camostat mesylate partially blocks this expression of the SARS-CoV-2 S protein.

Reading the RNS one can gauge that the Affimer binding to both the spike and the released proteins block the SARS-CoV 2 expression. It’s actually nothing new in terms of process it’s just that it’s not be achieved with Affimer(s) yet.

I suspect this will get Astra very excited as we are in the middle of a ‘turf war’ of big biotechs, to treat , slow down or inoculate Covid19 and only the cream amongst the minnows will make the big deals.

IF FOLK ACTUALLY READ THE RNS IT BASICALLY SAYS TO THE WORLD LOOK WHAT WE GOT!! £££

Excellent news!

For me the most important thing is this RNS now puts all the PI’s in profit. Gives them a nice cushion to sit back and enjoy the ride! ATB.

Trek

Be interesting to see where we close today. SP ran up towards results, dipped when opened as I suspect punters didn’t quite understand them, then it ticked up through the day. There is often a lag following results as they are absorbed, unless of course it’s a howler. But I think the market is yet to absorb how good these are and understandably so against the macro back drop and a general dumping of O&G stocks.... I think we could see 40p again v soon.

Trek

I have a decent holding here and there is much room for improvement in shareholder comms. Period!

Trek